Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells
about
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomasInsulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cellsBone morphogenetic protein-induced MSX1 and MSX2 inhibit myocardin-dependent smooth muscle gene transcriptionDermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage.Mig-6 gene knockout induces neointimal hyperplasia in the vascular smooth muscle cell.Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the ratThe effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines.Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.Differences in genetic signaling, and not mechanical properties of the wall, are linked to ascending aortic aneurysms in fibulin-4 knockout miceA disintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature.Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis.MicroRNA-145 regulates platelet-derived growth factor-induced human aortic vascular smooth muscle cell proliferation and migration by targeting CD40.Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.The epidermal growth factor receptor and its ligands in cardiovascular disease.Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress.Diversification of caldesmon-linked actin cytoskeleton in cell motility.Epiregulin: roles in normal physiology and cancerFractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signallingDemethylation of epiregulin gene by histone demethylase FBXL11 and BCL6 corepressor inhibits osteo/dentinogenic differentiation.Epiregulin can promote proliferation of stem cells from the dental apical papilla via MEK/Erk and JNK signalling pathways.p38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation of renal epithelial cells after oxidant injury.Gene expression studies demonstrate that the K-ras/Erk MAP kinase signal transduction pathway and other novel pathways contribute to the pathogenesis of cumene-induced lung tumors.
P2860
Q24656058-A077CBB0-CC92-4031-9D4D-8F26E58F0244Q28579027-E4832402-2054-4723-A52A-32CE2F19DA17Q28589105-BE6E62E9-45D1-4FB0-A125-D7A1DEB6C70CQ31111797-EDEBA026-D3BF-4C4E-BE5E-DCA8BFDBFD96Q34773853-A401591A-32CF-42E5-A0BD-AD7F72E52055Q34788065-8BCC87C7-1B18-4FEA-8D0B-FC0B68AF64DBQ35357793-37EA5E7D-166B-43EA-91C0-72D5EA44C237Q35671281-9338D638-08A2-4BB4-869D-2D7E573B23F5Q35676753-377DC6CA-1659-4714-97B9-3E04B79E53A4Q35817886-7084012F-25CC-441C-ADA9-10CA1D06F606Q35848839-600B15C7-49EC-4243-B391-697590C7D252Q36319377-83BE5D77-0FD0-48F6-B21B-95D411EB8347Q36879604-7903D05D-5364-4B2F-8776-6038A663B801Q37245959-4DC0D1E3-57B2-44D2-994E-E70D70FAC395Q37291330-EC4BD844-0437-4832-9D1F-8A05600427CEQ37736555-79680840-0764-4ECE-931E-CA6079642726Q37847039-D3457892-605D-446F-9A62-CFF4233A5F27Q38196137-392BEF8D-086B-4213-A61D-AF44B0732D74Q42155155-B15E4B91-034C-450E-8AF0-78CA0D9EE075Q43470464-C4DCE68D-B384-435C-8DC7-ABBF884FB014Q43857639-AC8FE86A-7376-4383-8CF2-91278B4B8B8AQ46410675-0D2BF199-9338-4C8C-887B-8BE047EFD4FFQ46468224-B5772656-56B5-4BCC-9912-0D052218C3F4
P2860
Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@ast
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en-gb
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@nl
type
label
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@ast
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en-gb
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@nl
prefLabel
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@ast
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en-gb
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@nl
P2093
P1433
P1476
Epiregulin as a major autocrin ...... d vascular smooth muscle cells
@en
P2093
Akira Kitabatake
Akira Ogawa
Ken'ichiro Hayashi
Kenji Sobue
Kenji Yoshida
Masahiko Yano
Masanori Takahashi
Morito Monden
Toshi Komurasaki
Wataru Nishida
P304
P356
10.1161/01.CIR.0000096482.02567.8C
P407
P577
2003-10-27T00:00:00Z